Shaw and Partners Research Flash Note: “Safety Study Provides Early Indication of Safety and Efficacy”
CYP has reported encouraging early safety and efficacy data in its Phase 1 trial of CYP-001 in GvHD. Shaw and Partners, forecasts, recommendation and 12 month TP ($1.20) remain unchanged. BUY.
Download Company Report